Inventor
Gregory William Endres
Inventor
Saline, MI, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07DHeterocyclic compounds23%
A61KPreparations for medical, dental or toiletry purposes15%
A61LMethods or apparatus for sterilising materials or objects in general11%
C07CAcyclic or carbocyclic compounds10%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
B63BShips or other waterborne vessels2%
C07HSugars2%
C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients2%
PatentTitleYear
11,066,361Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions202110,729,810Methods, systems, and compositions for promoting bone growth202010,556,862Difluorolactam compounds as EP202010,450,257Methods of synthesizing a prostacyclin analog201910,155,716Amine salts of a prostacyclin analog20189,908,834'Methods of synthesizing a prostacyclin analog'20189,890,104'Amine salts of a prostacyclin analog'20189,701,630'Difluorolactam compositions for EP4-mediated osteo related diseases and conditions'20179,688,627'Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20179,676,712'Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20179,487,478'Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20169,440,919'Difluorolactam compositions for EP4-mediated osteo related diseases and conditions'20169,180,116'Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20159,126,973'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20159,120,820'Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins'20158,680,327'Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites'20148,536,185'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20138,450,326'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20138,440,417'Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase'20138,063,240'Prostaglandin E1 and E2 analogs for the treatment of various medical conditions'20116,410,622'Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2021Based in Saline, MI, US· patent location history
2011–2021Patents assigned to CAYMAN CHEMICAL CO INC (19)· patent assignee history
2011–2014Patents assigned to ENDRES GREGORY W (4)· patent assignee history
2013–2015Patents assigned to BARRETT STEPHEN DOUGLAS (2)· patent assignee history
2013–2015Patents assigned to CISKE FRED LAWRENCE (2)· patent assignee history
2016–2020Patents assigned to MYOMETRICS LLC (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CAYMAN CHEMICAL CO INC | 19 | 2011–2021 |
| MYOMETRICS LLC | 5 | 2016–2020 |
| ENDRES GREGORY Wself | 4 | 2011–2014 |
| BARRETT STEPHEN DOUGLAS | 2 | 2013–2015 |
| CISKE FRED LAWRENCE | 2 | 2013–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Saline, MI, US | 21 | 2002–2021 |